Please click the links below to access a free personal copy of key clinical papers in the areas of gMG and NMOSD.

You will be asked for information to allow us deliver your personal copies to you and to help manage our copyright obligations.

gMG
SOLIRIS^® (eculizumab) is indicated for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients six years of age and older who are anti-acetylcholine receptor (AChR) antibody positive.

ULTOMIRIS^® (ravulizumab) is indicated as an add-on to standard therapy for the treatment of adult patients with gMG who are AChR antibody-positive.

NMOSD
SOLIRIS^® (eculizumab) is indicated for the treatment of NMOSD in adult patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease.

ULTOMIRIS^® (ravulizumab) is indicated in the treatment of adult patients with NMOSD who are anti-aquaporin 4 (AQP4) antibody-positive.

Ravulizumab EU Summary of Product Characteristics
Eculizumab EU Summary of Product Characteristics

Prescribing information may differ from country to country. Please refer to your locally approved label and take this into consideration when viewing this information. 


Adverse Event Reporting

Healthcare professionals are asked to report any suspected adverse reactions. Please report any adverse reactions via your national reporting system. Adverse events should also be reported to Alexion pharmaceuticals by the following link: https://contactazmedical.astrazeneca.com/